

MCB/OMD

TACTICAL EMERGENCY MEDICAL SERVICES PROTOCOL







Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Table of Contents

SECTION II Tactical Emergency Medical Services Protocol

- II.1 Purpose
- II.2 Training Requirements
- II.3 Medical Direction
- II.4 Special Policies and Procedures
 - II.4A Oral Hydration
 - II.4B IV Hydration
 - II.4C Advanced Airway
 - II.4D Tourniquets
 - II.4E Hemostatic Agents
 - II.4F Dental Care
 - II.4G Wound Closure
 - II.4H Over the Counter (OTC) Medications
 - II.41 Sleep-Wake Cycle Medications
 - II.4J Tranexamic Acid Administration
- II.5 Quality Improvement

Supplement Tactical Protocols (STP)

- II.6 Tourniquet
- II.7 Hemostatic Agent: Combat Gauze
- II.8 Dental Injuries
- II.9 Wound Closures: Dermabond
- II.10 Wound Closures: Staples
- II.11 Over the Counter (OTC) Medications
- II.12 Tranexamic Acid Administration
- II.13 Surgical Cricothyrotomy
- II.14 Junctional Tourniquet
- Appendix A Fluid Replacement Table
- Appendix B List of OTC and Authorized Medications
 - B.1 Operational vs Non-Operational Definition
 - **B.2 Operational Medications**
 - B.3 Acetaminophen (Tylenol)
 - B.4 Calcium Carbonate (TUMS)
 - **B.5** Cimetidine (Tagamet)
 - B.6 Clove Oil
 - B.7 Cyanoacrylate Tissue Adhesive (Dermabond)
 - B.8 Fexofenadine/Pseudoephedrine (Allegra-D)





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Table of Contents – Continued

- B.9 Ibuprofen (Motrin/Advil)
- B.10 Loperamide (Imodium)
- B.11 Naproxen (Aleve/Naprosyn)
- B.12 Omeprazole (Prilosec)
- B.13 Proparacaine / Tetracaine (Alcaine)
- B.14 Pseudoephedrine (Sudafed)
- **B.15 Non-Operational Medications**
- B.16 Dimenhydrinate (Dramamine)
- B.17 Diphenhydramine (Benadryl)
- B.18 Ondansetron (Zofran)
- B.19 Hemostatic Agent / Dressing (Combat Gauze)
- B.20 Tranexamic Acid (Cyklokapron)





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

PROTOCOL II.1: Purpose

- 1. The purpose of the Tactical Emergency Medical Services Unit (TEMS Unit) is to support law enforcement or homeland security operations by facilitating the health and safety of critical public safety personnel inside the perimeter of high risk, large-scale, and extended operations. These events may include, but not be limited to, high-risk search warrants, barricaded persons, hostage situations, extraordinary deployments, civil unrest, and Weapons of Mass Destruction events.
- 2. The Tactical Emergency Medical Support provider is not directly responsible for any person(s) outside the direct field of operations, whose care may safely be provided by local EMS agency.
- 3. These protocols supplement the current version of the Medical Control Board Treatment Protocols for EMS System for Metropolitan Oklahoma City & Tulsa and at the Office of the Medical Director (OMD) discretion, may incorporate other protocol components,
- 4. The Tactical Emergency Medical Services Protocols shall be used only by OMD credentialed Tactical Emergency Medical Medic who is sponsored by an OMD approved law enforcement agency and are operating under law enforcement command.
- 5. TEMS Providers at the ALS levels may administer the medications and perform the procedures listed in these protocols only after receiving specific training on their use and only under the direction of OMD or on-line Medical Control.
- 6. Once the patient is removed from the law enforcement perimeter of operation, the TEMS protocol will end, the Medical Control Board Treatment Protocols for EMS System for Metropolitan Oklahoma City & Tulsa will be implemented, and the transition of care will be made to the local EMS agency.
 - a. An exception may be made when the TEMS Provider's specialized training is needed to manage the patient's illness/injury, then the TEMS Provider shall ride to the hospital with the patient to maintain medications that are not specified by the Medical Control Board Treatment Protocols for EMS System for Metropolitan Oklahoma City & Tulsa.
 - b. If, during transport, TEMS personnel encounter a significant conflict between TEMS protocols and those of the transporting EMS agency, they will contact On-line Medical Control.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

PROTOCOL II.2: Training Requirements

- All TEMS Unit members will be certified by a National, State, and/or Local certifying agency in tactical pre-hospital medicine. Currently, the predominant certifying agencies are the Counter Narcotics Terrorism Operations Medical Support (CONTOMS) program granted by the Department of Defense in cooperation with the Uniformed Services Health Sciences Division of the United States Government and the National Tactical Operations Association (NTOA) TEMS course. MCB Credentialing requires NAEMT Tactical Emergency Casualty Care and an EMT-Tactical certification in addition to the current credentialing requirements.
- In the absence of a CONTOMS/NTOA program, OMD has approved the Rescue Training Inc. certified EMT-T class for substitution of the CONTOMS/NTOA certification. This is ONLY approved substitute course and must be approved by OMD.
- 3. All TEMS units will complete a minimum of 36 training hours per calendar year for the TEMS Unit members. 24 of these training hours will be tactical in nature. An additional 8 hours will address TEMS specific issues. The remaining four (4) hours needed to meet current EMT-T/Tactical Emergency Casualty Care (TECC) suggested standards will be determined by the TEMS Coordinator in conjunction with the OMD and may come from Continuing Education classes taught throughout the year by other medical components.
- 4. TEMS Unit members who fail to acquire the required number of training hours per calendar year will be restricted from participation until the required training hours can be successfully completed.
- 5. Continued failure to acquire the required number of training hours, attend scheduled training days, or respond to call-outs, will result in removal from the Unit.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

PROTOCOL II.3: Medical Direction

- 1. TEMS Unit members will operate under this protocol in conjunction with the medical protocols of the MCB.
- 2. All protocols that are considered to be standing orders in MCB protocols will also be considered standing orders for TEMS Unit members on assignment.
- 3. When necessary, TEMS Unit members will consult with on-line medical control physicians regarding patient care and should not hesitate to contact local EMS providers should the need arise.
- 4. The Medical Director must review and approve any additional special policies and procedures specific to the tactical environment.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

PROTOCOL II.4: Special Policies and Procedures

The Medical Director has approved the following special policies and procedures specific to the tactical environment:

- A. Oral Hydration
- B. IV Hydration
- C. Advanced Airway
- D. Tourniquets
- E. Hemostatic Agents
- F. Dental Care
- G. Wound Closure
- H. Over the Counter Medications
- I. Sleep-Wake Cycle Medications
- J. Tranexamic Acid Administration
- K. Occlusive Dressings for thoracic injuries





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

PROTOCOL II.4.A: Oral Hydration

1. Ideally, oral hydration should take place on a routine basis. The TEMS providers should reference the Fluid Replacement Guidelines for Warm Weather Training chart. (appendix A) These charts will then allow the TEMS provider to determine the volume of oral fluids to be administered on an hourly basis in conjunction with recommended work/rest cycles.





PROTOCOL II.4.B: IV Hydration

- 1. TEMS ALS providers, at their discretion, may initiate intravenous access on members of the supported Law Enforcement Special Operations personnel for the purposes of fluid hydration.
- 2. A total of 10 15 mL/kg of normal saline may be administered for the purposes of hydration prior to prolonged incidents and/or incidents during noticeably humid and/or warm weather.
- 3. In the event of clinical dehydration in any member of the supported Law Enforcement Special Operations team during an incident, the TEMS ALS provider shall recommend that member's removal from duty, initiate intravenous access, and deliver a total of 20 mL/kg normal saline with a maximum volume of two (2) liters. If the member's symptoms have resolved, that member may return to duty. If dehydration symptoms persist, the member should be treated per the Medical Control Board Treatment Protocols for EMS System for Metropolitan Oklahoma City & Tulsa.
- 4. At any time in the assessment and treatment for IV hydration, if contraindications exist to fluid therapy, the TEMS ALS provider shall consult the on-line medical control physician for further direction.





PROTOCOL II.4.C: Advanced Airway

- 1. TEMS providers in tactical environment may need to place an advanced airway. While in the indirect threat or If capnography is unavailable the I-GEL Airway will be the primary tool used for the advanced airway unless contra-indicated per Medical Control Board Treatment Protocols for EMS System for Metropolitan Oklahoma City & Tulsa.
- 2. Once the TEMS providers are in the cold zone the I-Gel can be converted to an endotracheal tube if the airway cannot be adequately maintained.
- 3. TEMS ALS providers while in the tactical environment may need to perform a surgical cricothyrotomy to manage life-threatening catastrophic airway events when standard tactical airway procedures cannot be performed or have failed.
- 4. See Supplement Tactical Protocol section for protocol on usage.





PROTOCOL II.4.D: Tourniquets

- 1. TEMS providers may need to place a tourniquet to stop bleeding when Life-threatening limb hemorrhage is not controlled with direct pressure or other simple measures.
- 2. Application in the tactical environment warrants placement of a tourniquet as the first line hemorrhage control device for a life-threatening limb hemorrhage.
- 3. See Supplement Tactical Protocol section for protocol on usage.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

PROTOCOL II.4.E: Hemostatic Agents

- 1. TEMS providers may need to apply a hemostatic agent to stop massive lifethreatening arterial external extremity or truncal bleeding that is uncontrolled by direct pressure, indirect pressure or tourniquet.
- 2. Application of hemostatic agents is intended to be used in the indirect threat environment.
- 3. See Supplement Tactical Protocol section for protocol on usage.





PROTOCOL II.4.F: Dental Care

- 1. TEMS providers, at their discretion, while in the tactical environment may need to treat general dental pain or minor dental emergencies in the protracted tactical environment.
- 2. All TEMS provider treatment of dental injuries should be considered a TEMPORARY treatment only. Refer the patient to a dentist for follow-up as soon as possible.
- 3. See Supplement Tactical Protocol section for protocol on usage.





PROTOCOL II.4.G: Wound Closure

- 1. TEMS ALS providers, at their discretion, while in the tactical environment and during prolonged incidents may need to close a wound.
- 2. The purpose of this policy is NOT to constitute definitive wound closure but to limit blood loss, pain and risk of secondary contamination / infection in an open wound.
- 3. See Supplement Tactical Protocol section for protocol on usage.



Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

PROTOCOL II.4.H: Over the Counter Medications

- 1. TEMS providers, at their discretion and upon the expressed desire of members of the sponsoring law enforcement Special Operations team, may make available approved OTC medications.
- 2. If a potentially sedating OTC is taken by a Special Operations team member that member will be considered non-operational as detailed in the Supplement Tactical Protocol section.
- 3. TEMS providers should ensure, to the best of their abilities that no contraindications exist to the Special Operations team member selected OTC medication.
- 4. In instance where TEMS providers deem treatment and evaluation beyond OTC medication, in the best interest of the Special Operations team member, they shall advise the Special Operations team member to seek such treatment and shall not make available OTC medication.
- 5. See appendix B for a list of OTC meds permitted by medical direction.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

PROTOCOL II.4.I: Sleep-Wake Cycle Meds

- 1. TEMS ALS providers, at their discretion, and during prolonged incidents that disrupt reasonable sleep-wake cycles of Special Operations team members, may dispense sleep-wake cycle medication as prescribed by the team Medical Director.
- 2. Special Operations team members rotation to promote reasonable sleep-wake cycles is recommended and highly preferred to the use of sleep-wake cycle medication.



Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

PROTOCOL II.4.J: Tranexamic Acid Administration

- 1. TEMS ALS providers while in the tactical environment may need to administer Tranexamic Acid to treat adults in sustained hemorrhagic shock.
- 2. See Supplement Tactical Protocol section for protocol on usage.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

PROTOCOL II.5: Quality Improvement

- 1. The TEMS coordinator will be responsible for maintaining all appropriate documentation for the TEMS Program.
- 2. The TEMS coordinator will be responsible for development and maintenance of a TEMS personnel and activity database.
- 3. Quarterly and annual review of Tactical EMS clinical skills competency will be performed by the TEMS coordinator, the System Medical Director or his representative. A quarterly report will be forwarded to the OMD for the necessary distribution in warranted situations.
- 4. The TEMS coordinator, along with the System Medical Director or his representative, will be responsible for making recommendations to the Office of the Medical Director for modifications to training programs, standing orders, etc.
- 5. All situations involving utilization of skills normally approved by verbal medical control orders shall be reviewed by the OMD. The exception shall be the distribution of approved over-the-counter medications to members of the law enforcement agency supported by the TEMS program.
- 6. All patients evaluated and treated by TEMS providers require the completion of an incident report, with the exception of self-administered over-the-counter medications. This incident report will be forwarded to the OMD for review. In event of multiple casualties, the TEMS provider shall provide an operational overview of the medical situation, subject to editing of potentially classified material by the involved law enforcement agency. Individual patient care reports will be completed by the transporting EMS personnel.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Supplement Tactical Protocols

The Medical Director has approved the following supplement tactical protocols specific to the tactical environment:

- II.6 Tourniquet
- II.7 Hemostatic Agent: Combat Gauze
- II.8 Dental Injuries
- II.9 Wound Closure: Dermabond
- II.10 Wound Closure: Staples
- II.11 Over the Counter Medications
- II.12 Tranexamic Acid Administration
- II.13 Surgical Cricothyrotomy
- II.14 Junctional Tourniquet





STP: PROTOCOL II.6: Tourniquet

- 1. **Setting:** Prehospital and hospital
- 2. **Indications for tourniquet use:** to stop bleeding when Life-threatening limb hemorrhage is not controlled with direct pressure or other simple measures, as may occur with a mangled extremity or partial/complete traumatic amputation has occurred.

3. Application during direct threat phase:

i. Apply the tourniquet over the uniform proximal to the bleeding site. Initial tourniquet placement should be as high as possible on the limb.

ii. Combat Application Tourniquet (CAT)

- i. Placement
 - i. Route the self-adhering band around the extremity.
 - ii. Pass the band through the slit of the buckle.
 - iii. Pull the self-adhering band tight.
 - iv. Twist the rod until bleeding is controlled.
 - v. Lock the rod in place with the clip.
 - vi. Record the date/time of application on the tourniquet.

iii. SOF-T Wide

i. Placement

- i. Route the band around the extremity.
- ii. Clip the buckles together.
- iii. Pull the band tight.
- iv. Twist the rod until bleeding is controlled.
- v. Lock the rod in place within the Tri-ring.
- vi. Record the time of application on the tourniquet.

4. Evaluation

- i. The tourniquet is effectively applied when there is cessation of bleeding from the injured extremity, indicating total occlusion of arterial blood flow.
- ii. Any pre-existing distal pulse should be absent at that time as well.

5. Application during Indirect Threat Phase.

- i. If tourniquet not yet applied to control life-threatening external hemorrhage i. place a tourniquet as described above
- ii. If Tourniquet already placed and there is a delay in TACEVAC.
 - i. Properly place a second tourniquet next to the first tourniquet (touching without overlapping) then secure.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

STP: PROTOCOL II.6: Tourniquet (Cont.)

- ii. Evaluate the wound for continued hemorrhage control.
- iii. If hemorrhage control not maintained; reevaluate tourniquets for appropriate tightness.

6. Tourniquet time and removal

- i. Tourniquets should be removed as soon as possible under conditions where the hemorrhage can be directly controlled.
- ii. Tourniquet placement must be communicated in patient reports for all prehospital to hospital and inter-hospital transfers.
- iii. Tourniquet time > 6 hours is associated with 50% distal tissue loss

7. Training:

i. Appropriate tourniquet use requires initial and annual renewal training with skill demonstration. OMD must approve and evaluate the initial training



Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions



STP: PROTOCOL II.7: Hemostatic Agent : Combat Gauze

- 1. Setting: Tactical environment
- 2. **Indications for Hemostatic agents use:** to stop massive life-threatening arterial extremity or junctional bleeding that is uncontrolled by direct pressure, indirect pressure.

3. Application:

- i. Expose the wound by removing clothing in proximity to the injury.
- ii. Blot or scoop away excess blood away from the wound.
- iii. Immediately insert the gauze into the wound.
- iv. Pack the wound with the gauze until the wound cavity is full. If any excess, place the gauze on top of the wound.
- v. Apply FIRM pressure to the wound for 5 minutes.
- vi. If bleeding persists, remove gauze and insert a new roll of Combat Gauze to fill all voids in the wound cavity.
- vii. Cover the wound with a pressure dressing or equivalent dressing and maintain pressure.
- viii. Document the location and time the hemostatic agent was applied.

4. Evaluation

- i. The hemostatic agent is effectively applied when there is cessation of bleeding from the wound indicating total occlusion of blood flow.
- ii. Asses for Hypovolemia and treat accordingly.
- 5. **Training:** Appropriate hemostatic agent use requires initial and annual renewal training with skill demonstration. OMD must approve and evaluate the initial training.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

STP: PROTOCOL II.8: Dental Injuries

- 1. **Setting:** Tactical environment
- 2. **Indications for Treatment of Dental Injuries:** to stop intermittent or continuous dental pain or heat / cold sensitivity from a tooth injury.

3. Application:

- i. Record the assessment of the injury
- ii. Examine the surrounding tissues for other injury or missing pieces
- iii. Remove the fractured piece.
- iv. Place small rolls of gauze to hold the lip away from the tooth.
- v. Apply Eugenol (Oil of Cloves) on the broken surface to decrease the pain.
- vi. Mix zinc oxide powder and Eugenol into a putty-paste.
- vii. Cover the broken surface with the zinc oxide "cement."
- viii. Keep dry 10 minutes and allow hardening.
- ix. Smooth off any corners as the cement hardens.
- x. Use wax paper or plastic over surface and allow a gentle bite if an occlusive surface is involved.

4. Evaluation

- i. All EMS treatment of dental injuries should be considered a TEMPORARY treatment only.
- ii. Refer the patient to a dentist for follow-up as soon as possible.
- iii. Check for sharp edges and proper bite.
- iv. Evaluate for sensitivity to the treatment. Treat according to MCB Prehospital Operations Protocols if sensitivity found.
- 5. **Training:** Appropriate Dental injury protocol use requires initial and annual renewal training with skill demonstration. OMD must approve and evaluate the initial training.



Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

STP: PROTOCOL II.9: Wound closure (Dermabond)

- 1. Setting: Tactical environment
- 2. **Indications for Wound Closure:** To limit blood loss, pain, and risk of secondary contamination / injury to an open wound with a delay in transportation to definitive care will be or is anticipated to be several hours.

3. Application

- i. Expose the wound by removing clothing.
- ii. Blot away excess blood away from the wound with gauze.
- iii. Thoroughly clean the wound.
- iv. Hold the edges of the wound together to close the edges. Keep the edges together while applying the adhesive
- v. Crush the vial the Dermabond comes in with the thumb and index finger and turn it upside down.
- vi. Squeeze the vial gently while brushing the vial back and forth on the wound several times taking care not to insert the vial into the wound.
- vii. Allow the area to dry for 30 seconds and then repeat the application again allowing 30 more seconds.

4. Evaluation

- i. This is **not** intended to constitute definitive wound closure this will minimize the potential for increased infection risk and increased retained foreign body risk.
- ii. Advise patient of requirement for further evaluation by physician
- iii. Evaluate for the wound to be completely closed.
- iv. Evaluate for sensitivity to the adhesive. Treat according to MCB Prehospital Operating Protocols if sensitivity found.

5. Contraindications

- i. Grossly contaminated wounds
- ii. Greater than two hours since infliction of wound
- iii. Macerated/crushed surrounding tissue
- 6. **Training:** Appropriate wound closure protocol use requires initial and annual renewal training with skill demonstration. OMD must approve and evaluate the initial training.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

STP: PROTOCOL II.10: Wound Closures: Staples

- 1. **Setting:** Tactical environment
- 2. **Indications for Wound Closure:** To limit blood loss, pain, and risk of secondary contamination / injury to an open wound with a delay in transportation to definitive care will be or is anticipated to be several hours.

3. Application

- i. Expose the wound by removing clothing.
- ii. Blot away excess blood away from the wound with gauze.
- iii. Thoroughly clean the wound.
- iv. The edges of the wound are aligned and held together with forceps or fingers.
- v. The stapling device is held against the wound at the point at which the staple is to be placed.
- vi. By squeezing the trigger on the stapling device, the staple is automatically placed into the skin.

4. Evaluation

- i. This is **not** intended to constitute definitive wound closure this will minimize the potential for increased infection risk and increased retained foreign body risk.
- ii. Advise patient of requirement for further evaluation by physician
- iii. Evaluate for the wound to be completely closed.
- iv. Evaluate for sensitivity to the staples. Treat according to MCB Prehospital Operating Protocols if sensitivity found.

5. Contraindications

- i. Grossly contaminated wounds
- ii. Greater than six hours since infliction of wound
- iii. Macerated/crushed surrounding tissue
- 6. **Training:** Appropriate wound closure protocol use requires initial and annual renewal training with skill demonstration. OMD must approve and evaluate the initial training.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

STP: PROTOCOL II.11: Over the Counter (OTC) Medications

1. **Indications for usage:** Upon the expressed desire of members of the Special Operations team for OTC medications.

2. List of OTC medications available: (See Appendix B)

- i. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
 - 1. Ibuprofen (Motrin/Advil)
 - 2. Naproxen (Aleve/Naprosyn)
 - 3. Acetaminophen (Tylenol)
- ii. Antihistamines / Decongestants
 - 1. Fexofenadine + Pseudoephedrine (Allegra-D)
 - 2. Pseudoephedrine (Sudafed)
- iii. Gastrointestinal
 - 1. Cimetidine (Tagamet or equivalent H2 blocker)
 - 2. Omeprazole (Prilosec or equivalent Proton Pump Inhibitor)
 - 3. Loperamide (Imodium)
 - 4. Dimenhydrinate (Dramamine),
 - 5. 5-HT3 Antagonist (Zofran)
 - 6. TUMS (Calcium Carbonate)
- iv. Ophthalmologic
 - 1. Proparacaine or Tetracaine (Alcaine) ophthetic
- v. Topical dental analgesia
 - 1. Clove oil

3. Evaluation

- i. TEMS Providers shall **NOT** prescribe OTC medications.
- ii. If a potentially sedating OTC is taken by a tactical team member that member will be considered non-operational as detailed in the Supplement Tactical Protocol section
- iii. Ensure to the best of your abilities that no contraindications exist to tactical team member selected OTC medication,
- iv. In instance where it is deemed that the treatment and evaluation is beyond OTC medication, in the best interest of the Special Operations team member, tactical paramedics shall advise the Special Operations team member to seek such treatment and shall not make available OTC medication.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

STP: PROTOCOL II.12: Tranexamic Acid Administration

- 1. Setting: Tactical environment
- 2. **Indications:** In the setting of hemorrhagic shock from trauma less than 3 hours old with suspected need for massive blood transfusion due to marked internal or external blood loss with a sustained tachycardia 110 beats per minute or greater and sustained hypotension systolic BP 90 mmHg or less.
- 3. Application:
 - i. 2 GRAMS IVPB over 10 minutes.
 - ii. Administer in 100mL or 250mL NS.

4. Evaluation:

- i. Evaluate for sensitivity
- ii. Evaluate for infiltrated IV site

5. Contraindications:

- i. Non-hemorrhagic shock
- ii. Non-traumatic hemorrhagic shock
- iii. Hemorrhagic shock stabilized with other hemostatic agents/measures



Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions



STP: PROTOCOL II.13: Surgical Cricothyrotomy

- **1. Setting:** Tactical environment
- 2. Indications for Cricothyrotomy: To manage life-threatening catastrophic airway events when standard tactical airway procedures cannot be performed or have failed

3. Contraindications:

i. Under the age of 12 y/o

4. Application:

- i. Place the patient into a supine position
- ii. Have all supplies (including suction and BVM) available and ready
- iii. Locate the cricothyroid membrane utilizing correct anatomical landmarks
- iv. and prep the area
- v. With scalpel, make a 1.0 to 2.0 cm shallow, vertical incision over the skin from the thyroid cartilage to the cricoid cartilage
- vi. puncture the membrane by placing the scalpel in the middle of the membrane against the thyroid cartilage
- vii. Enlarge the incision by cutting the membrane with the scalpel to the left and then back to the right approximately ¼ inch in either direction
- viii. Using a tracheal hook to maintain the surgical opening, insert the cuffed tube into the trachea
- ix. Inflate the cuff with 5-10cc of air and ventilate the patient while manually stabilizing the tube
- x. Assess tube placement
- xi. Secure the tube

5. Evaluation:

- i. Evaluate for the wound for uncontrolled hemorrhage
- ii. Evaluate for proper ventilation support
- iii. Evaluate for the below stated complications

6. Complications:

- i. Soft tissue damage around the surgical site and to trachea
- ii. Failure to place tube into trachea
- iii. Placing the distal end of the tube in a superior direction.

7. Training:

- i. Appropriate surgical cricothyrotomy protocol use requires initial and annual renewal training with skill demonstration.
- ii. OMD must approve and evaluate the initial training.





STP: PROTOCOL II.14: Junctional Tourniquet

1. Indication(s):

i. Axillary and/or inguinal hemorrhage unable to be effectively controlled by other hemostatic measures. The junctional tourniquet may be first line hemorrhage control if indicated by clinical assessment.

2. Application:

ii. Axillary hemorrhage:

- a. Apply tourniquet in the axilla as high as possible.
- b. Place D-ring on injured side, aligning it with side of the neck.
- c. Connect buckle and secure strap in place by pulling the BROWN handles part until click is heard.
- d. Maintain tension and secure strap by pressing it down on Velcro.
- e. Attach extender to the Target Compression Device (TCD) prior to application and place strap on brown Velcro.
- f. Connect strap using large clip to D-ring on front of the tourniquet.
- g. Connect accessory strap to cord on back of the tourniquet using small clip, as close as possible to the patient's mid-line.
- h. Position TCD with extender directly under and parallel to the clavicle.
- i. Tighten strap as much as possible using the BROWN handle.
- j. Use hand pump to inflate the TCD while maintaining the correct position of the TCD until hemorrhage stops.
- k. TO REMOVE, unbuckle the belt. (Removal prior to ED arrival is NOT recommended.)
- I. Monitor and adjust as necessary.

iii. Inguinal hemorrhage:

- a. Remove objects from patient clothing pockets and pelvic area. Ideally, quickly remove clothing to fully expose bleeding area.
- b. Slide belt underneath the patient, positioning TCD over area to be compressed. **Note:** The belt may attach on the patient's left or right, depending on location of injury.
- c. Use gauze or hemostatic dressing (if available) targeting directly over the wound.
- d. For bi-lateral application, use a second TCD.
- e. Hold TCD in place and connect belt using the buckle.
- f. Pull the BROWN handles away from each other until buckle secures and click is heard.
- g. Fasten any excess belt in place by pressing it down on Velcro. A second click may be heard.
- h. Use hand pump to inflate TCD(s) until hemorrhage stops.
- i. TO REMOVE, unbuckle the belt. (Removal prior to ED arrival is NOT recommended.)
- j. Monitor and adjust as necessary.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

<u>Appendix A</u>

Fluid Replacement Guidelines for Warm Weather Training

HEAT INDEX

Heat Category	WBGT Index F ^o	Easy Work		Moderate Work		Hard Work	
		Work/ Rest	Water Intake, QT/HR	Work/ Rest	Water Intake, QT/HR	Work/ Rest	Water Intake, QT/HR
1	78-81.9	NL	1/2	NL	3⁄4	40/20	3⁄4
2 Green	82-84.9	NL	1⁄2	50/10	3/4	30/30	1
3 Yellow	85-87.9	NL	³ /4	40/20	³ /4	30/30	1
4 Red	88-89.9	NL	3⁄4	30/30	3⁄4	20/40	1
5 Black	>90	50/10	1	20/40	1	10/50	1

- > NL= no limit to work time per hour.
- Rest means minimal physical activity (sitting or standing) accomplished in shade, if possible.
- > CAUTION: Hourly fluid intake should not exceed 11/4 quarts.
- > Daily fluid intake should NOT exceed 12 liters.
- > Wearing body armor adds 5° F to WBGT Index.

You may obtain your WBGT from online calculators using data from a weather site (i.e. wunderground.com, weather.com, etc....), APPs (i.e. weatherFX), or using a WBGT thermometer.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Appendix B: List of OTC and Authorized Medications

The Medical Director has approved the following OTC and prescribed medications specific to the tactical environment:

Acetaminophen (Tylenol)

Calcium Carbonate (TUMS)

Cimetidine (Tagamet or equivalent H2 blocker)

Clove oil

Combat Gauze

Cyanoacrylate Tissue Adhesive (Dermabond)

Dimenhydrinate (Dramamine)

Diphenhydramine (Benadryl)

Fexofenadine + Pseudoephedrine (Allegra-D)

Ibuprofen (Motrin/Advil)

Loperamide (Imodium)

Naproxen (Aleve/Naprosyn)

omeprazole (Prilosec or equivalent Proton Pump Inhibitor)

Ondansetron (Zofran)

Pseudoephedrine (Sudafed)

Proparacaine or Tetracaine (Alcaine) ophthetic

Tranexamic Acid





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Appendix B.1 Definitions of Operational vs. Non-operational

OPERATIONAL:

The medication when taken by a Law Enforcement member who may continue to perform his/her assigned duties.

NON-OPERATIONAL:

Once the medication has been administered, the Law Enforcement member is removed from his/her assigned duties since the medication or the associated medical/traumatic complaint may impair his/her ability to perform critical Law Enforcement tasks and duties.





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

<u>Appendix B.3</u> Acetaminophen (Tylenol)

AVAILABILITY:

- i. 325mg Tablet
- ii. 500mg Tablet

ACTION:

i. Pain medication

INDICATIONS:

i. Mild to moderate pain

CONTRAINDICATIONS:

- i. Known hypersensitivity
- ii. Liver disease
- iii. PUD/GERD/GI bleed

PRECAUTIONS:

- i. Sensitivity
- ii. Passes through Breast Milk

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

i. GI upset

INTERACTIONS:

DOSAGE:

i. 650-1000mg Q4 to 6 hours PO





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

<u>Appendix B.4</u> Calcium Carbonate (TUMS)

AVAILABILITY:

- i. 500mg (Tums Regular, Tums Freshers)
- ii. 750mg (Tums Extra, Tums Kids, Tums Smoothies)
- iii. 1000mg (Tums Ultra)
- iv. 1177mg (Tums Chewy Delights)

ACTION:

i. neutralizes hydrochloric acid in gastric secretions

INDICATIONS:

i. PUD / GERD

CONTRAINDICATIONS:

- i. Known hypersensitivity
- ii. Ceftriaxone administration

PRECAUTIONS:

i. Renal calculi

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

INTERACTIONS:

DOSAGE:

i. 2 to 3 tablets chewed as symptoms occur; not to exceed 7 tablets per day



Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions



Appendix B.5: Cimetidine (Tagamet)

AVAILABILITY:

- i. 200, 300, 400mg tablet
- ii. 300mg IV/IM

ACTION:

i. Proton pump inhibitor

INDICATIONS:

- i. PUD / GERD
- ii. Esophagitis
- iii. Gastritis

CONTRAINDICATIONS:

- i. Known hypersensitivity
- ii. Concomitant H-2 blocker use

PRECAUTIONS:

OPERATIONAL STATUS:

i. Operational


SIDE EFFECTS:

INTERACTIONS:

DOSAGE:

- i. 200mg IV/IM/PO every 6-8 hours
- ii. 300mg IV/IM/PO every 6-8 hours
- iii. 400mg twice daily







<u>Appendix B.6</u> Clove Oil

AVAILABILITY:

i. Topical Liquid (OTC)

ACTION:

i. Topical (dental) anesthetic

INDICATIONS:

i. Dental pain / injury

CONTRAINDICATIONS:

i. Known hypersensitivity

PRECAUTIONS:

i. Penetrating / open intra-oral wounds

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

INTERACTIONS:

DOSAGE:

i. 0.1cc Topically





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Appendix B.7 Cyanoacrylate Tissue Adhesive (Dermabond)

AVAILABILITY:

i. Single use ampoules

ACTION:

i. Tissue adhesive

INDICATIONS:

i. Minor trauma

CONTRAINDICATIONS:

i. Known hypersensitivity

PRECAUTIONS:

i. Avoid near eyes

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

i. Transient local discomfort

INTERACTIONS:

i. N/A

DOSAGE:

i. As required for wound closure, 2-4 layered applications





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Appendix B.8 Fexofenadine & Pseudoephedrine (Allegra-D)

AVAILABILITY:

i. Fexofenadine HCL 60mg / Pseudoephedrine HCL 120mg Tablet

ACTION:

i. Non-sedating antihistamine with decongestant

INDICATIONS:

i. Allergy symptoms with nasal congestion / symptoms

CONTRAINDICATIONS:

- i. Known hypersensitivity
- ii. Current MAOI use

PRECAUTIONS:

- i. Hypertension history
- ii. Cardiac History

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

INTERACTIONS:

DOSAGE:

i. 1 Tablet q12hrs PO



Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

<u>Appendix B.9</u> Ibuprofen (Motrin/Advil)

AVAILABILITY:

- i. Tablet: 200mg (OTC)
- ii. 100mg/5ml suspension

ACTION:

i. Non-steroidal anti-inflammatory pain medication

INDICATIONS:

i. Mild to moderate pain

CONTRAINDICATIONS:

- i. Known hypersensitivity
- ii. Renal insufficiency (not failure)
- iii. PUD/GERD/GI bleed history

PRECAUTIONS:

- i. Do not use with other NSAIDs
- ii. Caution with concomitant steroid use.
- iii. aL CB (D in 3rd trimester) ^a+

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

- i. GI upset / nausea
- ii. GI bleeding risk

INTERACTIONS:

DOSAGE:

i. 400-600mg PO





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Appendix B.10 Loperamide (Imodium)

AVAILABILITY:

i. Tablet: 2mg (OTC) and 1mg/5ml suspension

ACTION:

i. Anti-diarrheal

INDICATIONS:

i. Diarrhea

CONTRAINDICATIONS:

- i. Known hypersensitivity
- ii. Hypertension
- iii. Bloody diarrhea

PRECAUTIONS:

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

i. ENT-dryness

INTERACTIONS:

- ii. 4mg first dose
- iii. 2mg each subsequent episode until stool formed; maximum 16mg per day





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

<u>Appendix B.11</u> Naproxen (Aleve/Naprosyn)

AVAILABILITY:

i. 220 / 375 / 500mg Tablet

ACTION:

i. Non-steroidal anti-inflammatory pain medication

INDICATIONS:

i. Mild to moderate pain

CONTRAINDICATIONS:

- i. Known hypersensitivity
- ii. Renal insufficiency (not failure)
- iii. PUD/GERD/GI bleed history

PRECAUTIONS:

- i. Do not use with other NSAIDs
- ii. Caution with concomitant steroid use.
- iii. aL CB (D in 3rd trimester) ^a+

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

- i. GI upset / nausea
- ii. GI bleeding risk

INTERACTIONS:

DOSAGE:

i. 220-500mg q12 hrs





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

<u>Appendix B.12</u> Omeprazole (Prilosec)

AVAILABILITY:

i. 20mg, 40mg (OTC) Capsule

ACTION:

i. Proton pump inhibitor

INDICATIONS:

- i. PUD / GERD
- ii. Esophagitis
- iii. Gastritis

CONTRAINDICATIONS:

- i. Known hypersensitivity
- ii. Concomitant H-2 blocker use

PRECAUTIONS:

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

INTERACTIONS:

DOSAGE:

i. 40mg q day PO



Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions



Appendix B.13 Proparacaine / Tetracaine (Alcaine)

AVAILABILITY:

i. Ocular anesthetic solution

ACTION:

i. Topical anesthetic

INDICATIONS:

- i. To facilitate eye exam
- ii. Relieve eye pain
- iii. per MD/DO

CONTRAINDICATIONS:

i. Known hypersensitivity

PRECAUTIONS:

i. Insure eye protection from foreign objects after exam

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

i. Eye pain

INTERACTIONS:

- i. 1-2 drops per eye Topically
- ii. per MD/DO





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Appendix B.14 Pseudoephedrine (Sudafed)

AVAILABILITY:

i. 30mg; 60mg (OTC) Tablet

ACTION:

i. Decongestant

INDICATIONS:

- i. Nasal congestion
- ii. Rhinorrhea

CONTRAINDICATIONS:

- i. Known hypersensitivity
- ii. Hypertension

PRECAUTIONS:

OPERATIONAL STATUS:

i. Operational

SIDE EFFECTS:

i. Insomnia

INTERACTIONS

DOSAGE:

i. 30mg to 60mg q4 to 6 hrs or PRN, PO





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Appendix B.15 Non-Operational Medications

The Medical Director has approved the following Over the Counter Medications specific to the tactical environment to be considered a Non-Operational Medication:

Dimenhydrinate (Dramamine) Diphenhydramine (Benadryl) Ondansetron(Zofran) Tranexamic Acid





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

<u>Appendix B.16</u> Dimenhydrinate (Dramamine)

AVAILABILITY:

- i. IM/IV injectable
- ii. 50mg tablet

ACTION:

- i. Anti-emetic
- ii. Anti-motion sickness

INDICATIONS:

i. Nausea / vomiting

CONTRAINDICATIONS:

i. Known hypersensitivity

PRECAUTIONS:

i. May see sedation

OPERATIONAL STATUS:

i. NON-OPERATIONAL <u>4 hrs</u>

SIDE EFFECTS:

i. Sedation

INTERACTIONS:

- i. 50-100mg IM/IV/PO q4 hours or PRN
- ii. Per MD/DO



Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

<u>Appendix B.17</u> Diphenhydramine (Benadryl)

AVAILABILITY:

- i. IM/IV injectable
- ii. 25mg tablet

ACTION:

- i. H1-receptor antagonist
- ii. antihistamine

INDICATIONS

- i. Allergic conditions
- ii. Motion sickness
- iii. Vertigo,
- iv. Drug induced extra pyramidal reactions

CONTRAINDICATIONS:

- i. Known hypersensitivity
- ii. Asthma

PRECAUTIONS:

- i. May see sedation
- ii. Disturbed coordination
- iii. Tremors
- iv. Thickened bronchial secretions
- v. Wheezing

OPERATIONAL STATUS:

i. NON-OPERATIONAL 6 hrs

SIDE EFFECTS:


i. Sedation

INTERACTIONS:

i. other CNS depressants and MAOIs compound CNS depression

- i. 25-50mg IM/IV/PO q4-6 hrs or PRN
- ii. Per MD/DO







Appendix B.18 Ondansetron (Zofran)

AVAILABILITY:

- i. IM/IV injectable
- ii. 4mg tablets

ACTION:

- i. Anti-emetic
- ii. Anti-motion sickness

INDICATIONS:

i. Nausea / vomiting

CONTRAINDICATIONS:

i. Known hypersensitivity

PRECAUTIONS:

- i. May see sedation
- ii. Dizziness
- iii. Light-headedness,
- iv. Headache
- v. Diarrhea
- vi. Constipation
- vii. Dry mouth

OPERATIONAL STATUS:

i. NON-OPERATIONAL 8 hrs

SIDE EFFECTS:

i. Sedation

INTERACTIONS:

i. Rifampin may decrease Ondansetron levels

- i. 4mg slow IVP or IM Q q 8 hrs 8-16 mg
- ii. 4mg PO q 8hrs
- iii. Per MD/DO





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

Appendix B.19

Hemostatic Agent or Impregnated Dressing (Combat Gauze)

AVAILABILITY:

- i. Gauze
- ii. Single use packets

ACTION:

i. Blood clotting aid

INDICATIONS:

i. Massive Hemorrhage

CONTRAINDICATIONS:

i. Known hypersensitivity

PRECAUTIONS:

i. Standard / Universal precautions for wound care

OPERATIONAL STATUS:

i. NON-OPERATIONAL unless bleeding is controlled and there is no apparent life threat

SIDE EFFECTS:

INTERACTIONS:

DOSAGE:

i. Single or multiple packet(s) applied into bleeding wound





Approved 3/5/2025, Effective Date: 3/5/2025, replaces 2/3/18 & all prior versions

<u>Appendix B.20</u> Tranexamic Acid (TXA, Cyklokapron)

AVAILABILITY:

i. 2 gram/10mL vial or ampule (100mg/mL)

ACTION:

i. Promotes clot formation in the setting of massive hemorrhage.

INDICATIONS:

i. Adults in hemorrhagic shock

CONTRAINDICATIONS:

- i. Non-hemorrhagic shock
- ii. Non-traumatic hemorrhagic shock
- iii. Hemorrhagic shock stabilized with other hemostatic agents/measures

PRECAUTIONS:

OPERATIONAL STATUS:

i. NON-OPERATIONAL No End Time

SIDE EFFECTS:

i. While a theoretical concern, TXA has not been shown to cause significant increase in deep venous thrombosis, pulmonary embolism, myocardial infarction, or stroke in published trials to date.

DOSAGE:

i. 2 GRAM IVPB over 10 minutes. Administer in 100mL or 250mL NS.